Development of nanocarriers for cancer thermochemotherapy
Project/Area Number |
25350549
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Biomedical engineering/Biomaterial science and engineering
|
Research Institution | Tohoku University |
Principal Investigator |
Morimoto Nobuyuki 東北大学, 工学(系)研究科(研究院), 准教授 (00313263)
|
Co-Investigator(Renkei-kenkyūsha) |
SUZUKI Makoto 東北大学, 大学院工学研究科, 教授 (60282109)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | ナノキャリア / 刺激応答性 / スルホベタインポリマー / 温熱化学療法 / 自己組織化 / ベタイン型ポリマー / ナノ粒子 / 細胞毒性 / ベタイン型コポリマー / ベタイン |
Outline of Final Research Achievements |
Copolymers of 3-dimethyl(methacryloyloxyethyl)ammonium propanesulfonate and poly(ethylene glycol) methacrylate were prepared to develop cancer thermochemotherapy. Among these polymers, the random copolymers formed nanospheres self-assembly in physiological solution conditions. Moreover, the random polymers exhibited little cytotoxicity and effective cellular uptake based on membrane translocation as the main pathway of internalization. The polymer was effectively internalized into cells even after conjugation with doxorubicine, a cancer drug. The conjugated polymer exhibited the cell killing activity without reducing the drug efficacy and induced apoptosis of cancer cells.
|
Report
(4 results)
Research Products
(29 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Mg/Ca 結合 F-アクチンの多重水和状態2015
Author(s)
R. Chishima, A. Imao, G. Mogami, T. Watanabe, T. Wazawa, N. Morimoto, M. Suzuki
Organizer
第53回日本生物物理学会年会
Place of Presentation
金沢大学、金沢
Year and Date
2015-09-13
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-